Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer.

Moeremans K, Caekelbergh K, Annemans L.

Value Health. 2004 Jul-Aug;7(4):472-81.

2.

Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?

Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D.

Urology. 2005 Oct;66(4):835-9.

PMID:
16230148
3.

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.

Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson JE, Persson BE, Carroll K; Scandinavian Prostatic Cancer Group (SPCG)..

Eur Urol. 2002 Sep;42(3):204-11.

PMID:
12234503
4.

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group..

J Urol. 2002 Aug;168(2):429-35. Erratum in: J Urol 2002 Dec;168(6):2558. J Urol 2002 Oct;168;4(Pt 1):1510.

PMID:
12131282
5.

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.

Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C; 'Casodex' Early Prostate Cancer Trialists Group..

Radiother Oncol. 2005 Jul;76(1):4-10.

PMID:
16145740
6.

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.

Kolvenbag GJ, Blackledge GR, Gotting-Smith K.

Prostate. 1998 Jan 1;34(1):61-72. Review.

PMID:
9428389
7.

The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.

See WA, Tyrrell CJ; CASODEX Early Prostate Cancer Trialists' Group..

J Cancer Res Clin Oncol. 2006 Aug;132 Suppl 1:S7-16.

PMID:
16896884
8.

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.

Wirth M, Tyrrell C, Wallace M, Delaere KP, Sánchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T, Stone A.

Urology. 2001 Aug;58(2):146-51.

PMID:
11489683
9.

Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.

See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T.

Eur Urol. 2003 Nov;44(5):512-7; discussion 517-8.

PMID:
14572747
10.

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.

Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group..

Urology. 2004 May;63(5):928-33.

PMID:
15134983
11.

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.

Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group..

J Urol. 2004 Nov;172(5 Pt 1):1865-70.

PMID:
15540740
12.

[Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].

Rigatti P, Scattoni V.

Recenti Prog Med. 2002 Mar;93(3):183-5. Italian. No abstract available.

PMID:
11942171
13.

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

Wellington K, Keam SJ.

Drugs. 2006;66(6):837-50. Review. Erratum in: Drugs. 2006;66(15):1987.

PMID:
16706554
14.

The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.

McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J.

J Urol. 2006 Jul;176(1):75-80.

PMID:
16753373
15.

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group..

BJU Int. 2006 Feb;97(2):247-54.

16.

Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.

Wirth M, Tyrrell C, Delaere K, Sánchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns C, Borchers T, Morris T, Armstrong J; 'Casodex' Early Prostate Cancer Trialists' Group..

Prostate Cancer Prostatic Dis. 2005;8(2):194-200.

PMID:
15931272
17.

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.

Iversen P, Johansson JE, Lodding P, Kylmälä T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong J; Scandinavian Prostate Cancer Group..

Scand J Urol Nephrol. 2006;40(6):441-52.

PMID:
17130095
18.

The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.

Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M.

J Urol. 2005 Aug;174(2):547-52; discussion 552.

PMID:
16006889
19.

Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.

Wirth M, Tyrrell C, Delaere K, Sánchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns CF, Navani S, Armstrong J.

Prostate Cancer Prostatic Dis. 2007;10(1):87-93. Epub 2006 Nov 14.

PMID:
17102802
20.

[Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].

Martorana G.

Recenti Prog Med. 2002 Mar;93(3):179-82. Italian. No abstract available.

PMID:
11942170

Supplemental Content

Support Center